ArriVent BioPharma (AVBP) Accumulated Expenses (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Accumulated Expenses data on file, last reported at $16.2 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 943.83% year-over-year to $16.2 million; the trailing twelve-month figure through Mar 2026 stood at $16.2 million (up 943.83% YoY), and the FY2025 full-year result was $20.0 million, up 380.35% from the prior year.
• Accumulated Expenses eased to $16.2 million in Q1 2026, from $20.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $20.0 million in Q4 2025 to a low of $1.5 million in Q1 2025.
• A 4-year average of $8.6 million and a median of $6.3 million in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses tumbled 72.98% in 2025 and jumped 943.83% in 2026, its largest moves.
• Tracing AVBP's Accumulated Expenses over 4 years: stood at $3.4 million in 2023, then increased by 24.16% to $4.2 million in 2024, then surged by 380.35% to $20.0 million in 2025, then slipped by 19.14% to $16.2 million in 2026.
• Business Quant data shows AVBP's Accumulated Expenses at $16.2 million in Q1 2026, $20.0 million in Q4 2025, and $10.8 million in Q3 2025.